LTR Pharma Limited
Research LTR Pharma Limited (LTP.AX) on Bullrun: market cap AUD 85.67M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLTP.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 85.67M
- Financial periodFY2025
- RevenueAUD 145.78K
- Net income-AUD 5.59M
- Free cash flow-AUD 4.45M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 85.67M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 145.78K | -AUD 5.59M | -AUD 4.45M | 100.0% | -0.03 | AUD 31.81M | n/a | AUD 31.51M |
| FY2024 | n/a | -AUD 6.95M | -AUD 5.09M | n/a | -0.05 | AUD 3.10M | n/a | AUD 2.94M |
| FY2023 | n/a | -AUD 1.45M | -AUD 1.54M | n/a | -0.01 | AUD 7.14M | n/a | AUD 7.49M |
| FY2022 | n/a | -AUD 1.03M | -AUD 568.18K | n/a | -0.01 | AUD 1.91M | n/a | AUD 1.77M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 85.67M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About LTR Pharma Limited
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is LTR Pharma Limited's market cap?
LTR Pharma Limited's market capitalization is AUD 85.67M.
What does LTR Pharma Limited do?
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.